The treatment of melasma: A review of clinical trials

Journal of the American Academy of Dermatology

Volumn 55, Issue 6, 2006, Pages 1048-1065

  Gupta, Aditya K ^a,b   Gover, Melissa D ^b   Nouri, Keyvan ^c   Taylor, Susan ^d,e  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^b MEDIPROBE RESEARCH INC   (Canada)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^d Skin of Color Center   (United States)

^e Columbia University ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 HYDROXYACID; ADAPALENE; ASCORBIC 2 PHOSPHATE; ASCORBIC ACID DERIVATIVE; AZELAIC ACID; BETAMETHASONE VALERATE; CATECHOL DERIVATIVE; CLAIRISSIME; CLOBETASOL PROPIONATE; CORTICOSTEROID; DEXAMETHASONE ACETATE; DRULA FADE; ESOTERICA; ETRETIN; ETRETINATE; FLAVONOID; FLUOCINOLONE; GLYCOLIC ACID; HYDROQUINONE; HYDROQUINONE PLUS TRETINOIN PLUS FLUOCINOLONE ACETONIDE; ISOPROPYLCATECHOL; ISOTRETINOIN; KOJIC ACID; N ACETYL 4 CYSTEAMINYLPHENOL; NEOSTRATA; NUQUIN; OBAGI; PHENOL DERIVATIVE; PROANTHOCYANIDIN DERIVATIVE; PYCNOGENOL; RESORCINOL; RETINOIC ACID; SALICYLIC ACID; SEEQUIN; SOLAQUIN; SUNSCREEN; TRI LUMA; TRICHLOROACETIC ACID; ULTRAPLUS; ULTRAQUIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANTEX; VIQUIN;

ASTHMA; BURNING SENSATION; CHEMICAL BURN; CHLOASMA; CLINICAL TRIAL; COLLOID MILIUM; DEPIGMENTATION; DERMATITIS; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; EPIDERMAL HYPERMELANOSIS; ERYTHEMA; EXFOLIATIVE DERMATITIS; HERPES LABIALIS; HUMAN; HYPERPIGMENTATION; HYPERTRICHOSIS; HYPOPIGMENTATION; INTENSE PULSED LIGHT THERAPY; KERATOSIS; KERATOSIS PILARIS; LOW LEVEL LASER THERAPY; MELANOSIS; OCHRONOSIS; PAPULE; PERIORAL DERMATITIS; PHOTOTHERAPY; PRIORITY JOURNAL; PRURITUS; PUSTULE; RETINOID DERMATITIS; REVIEW; ROSACEA; SIDE EFFECT; SKIN ABRASION; SKIN ALLERGY; SKIN ATROPHY; SKIN IRRITATION; SKIN SENSITIZATION; SUNBURN; TELANGIECTASIA; ULTRAVIOLET A RADIATION; ULTRAVIOLET B RADIATION; VITILIGO; XEROSIS; YAG LASER;

ADRENAL CORTEX HORMONES; ADULT; CHEMEXFOLIATION; CLINICAL TRIALS; COMBINED MODALITY THERAPY; DERMABRASION; DICARBOXYLIC ACIDS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; FLAVONOIDS; GONADAL STEROID HORMONES; HUMANS; HYDROQUINONES; LASER COAGULATION; MELANOSIS; PHOTOTHERAPY; PREGNANCY; PREGNANCY COMPLICATIONS; PYRONES; RANDOMIZED CONTROLLED TRIALS; SKIN; SUNLIGHT; TREATMENT OUTCOME; TRETINOIN; ULTRAVIOLET RAYS;

EID: 33750835911     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2006.02.009     Document Type: Review

References (84)

1. In: Nordlund J.J., Boissy R.E., Hearing V.J., King R.A., and Ortonne J.P. (Eds). The pigmentary system physiology and pathophysiology (1998), Oxford University Press, New York
2. Goh C.L., and Dlova C.N. A retrospective study on the clinical presentation and treatment outcome of melasma in a tertiary dermatological referral center in Singapore. Singapore Med J 40 (1999) 455-458
3. Grimes P.E. Melasma: etiologic and therapeutic considerations. Arch Dermatol 131 (1995) 1453-1457
4. Sanchez N.P., Pathak M.A., Sato S., Fitzpatrick T.B., Sanchez J.L., and Mihm Jr. M.C. Melasma: a clinical, light microscopic, ultrastructural, and immunofluorescence study. J Am Acad Dermatol 4 (1981) 698-710
5. Taylor S.C. Epidemiology of skin diseases in people of color. Cutis 71 (2003) 271-275
6. Pandya A.G., and Guevara I.L. Disorders of hyperpigmentation. Dermatol Clin 18 (2000) 91-98 ix
7. Urabe K., Nakayama J., and Hori Y. Mixed epidermal and dermal hypermelanoses. In: Nordlund J.J., Boissy R.E., Hearing V.J., King R.A., and Ortonne J.P. (Eds). The pigmentary system physiology and pathology (1998), Oxford University Press, New York 909-913
8. Vazquez M., Maldonado H., Benmaman C., and Sanchez J.L. Melasma in men: a clinical and histologic study. Int J Dermatol 27 (1988) 25-27
9. Sodhi V.K., and Sausker W.F. Dermatoses of pregnancy. Am Fam Physician 37 (1988) 131-138
10. Resnik S. Melasma induced by oral contraceptive drugs. JAMA 199 (1967) 95-99
11. Lutfi R.J., Fridmanis M., Misiunas A.L., Pafume O., Gonzalez E.A., Villemur J.A., et al. Association of melasma with thyroid autoimmunity and other thyroidal abnormalities and their relationship to the origin of the melasma. J Clin Endocrinol Metab 61 (1985) 28-31
12. Perez M., Sanchez J.L., and Aguilo F. Endocrinologic profile of patients with idiopathic melasma. J Invest Dermatol 81 (1983) 543-545
13. Kang W.H., Yoon K.H., Lee E.S., Kim J., Lee K.B., Yim H., et al. Melasma: histopathological characteristics in 56 Korean patients. Br J Dermatol 146 (2002) 228-237
14. Wolf R., Wolf D., Tamir A., and Politi Y. Melasma: a mask of stress. Br J Dermatol 125 (1991) 192-193
15. Gano S.E., and Garcia R.L. Topical tretinoin, hydroquinone, and betamethasone valerate in the therapy of melasma. Cutis 23 (1979) 239-241
16. Maeda K., Naganuma M., Fukuda M., Matsunaga J., and Tomita Y. Effect of pituitary and ovarian hormones on human melanocytes in vitro. Pigment Cell Res 9 (1996) 204-212
17. Sarkar R., Jain R.K., and Puri P. Melasma in Indian males. Dermatol Surg 29 (2003) 204
18. Gilchrest B.A., Fitzpatrick T.B., Anderson R.R., and Parrish J.A. Localization of malanin pigmentation in the skin with Wood's lamp. Br J Dermatol 96 (1977) 245-248
19. Salim A., Rengifo-Pardo M., Vincent S., and Cuervo-Amore L. Melasma. In: Williams H., Bigby M., Diepgen T., Herxheimer A., Naldi L., and Rzany B. (Eds). Evidence-based dermatology (2003), BMJ Books, London 553-567
20. Piamphongsant T. Treatment of melasma: a review with personal experience. Int J Dermatol 37 (1998) 897-903
21. Pathak M.A., Fitzpatrick T.B., and Kraus E.W. Usefulness of retinoic acid in the treatment of melasma. J Am Acad Dermatol 15 (1986) 894-899
22. Vazquez M., and Sanchez J.L. The efficacy of a broad-spectrum sunscreen in the treatment of melasma. Cutis 32 (1983) 92, 95-6
23. Palumbo A., d'Ischia M., Misuraca G., and Prota G. Mechanism of inhibition of melanogenesis by hydroquinone. Biochim Biophys Acta 1073 (1991) 85-90
24. Amer M., and Metwalli M. Topical hydroquinone in the treatment of some hyperpigmentary disorders. Int J Dermatol 37 (1998) 449-450
25. Haddad A.L., Matos L.F., Brunstein F., Ferreira L.M., Silva A., and Costa Jr. D. A clinical, prospective, randomized, double-blind trial comparing skin whitening complex with hydroquinone vs placebo in the treatment of melasma. Int J Dermatol 42 (2003) 153-156
26. Hurley M.E., Guevara I.L., Gonzales R.M., and Pandya A.G. Efficacy of glycolic acid peels in the treatment of melasma. Arch Dermatol 138 (2002) 1578-1582
27. AHFS drug information (2004), American Society of Health-System Pharmacists Inc, Bethesda, MD pp. 3415, 3463-6
28. Bentley-Phillips B., and Bayles M.A. Cutaneous reactions to topical application of hydroquinone: results of a 6-year investigation. S Afr Med J 49 (1975) 1391-1395
29. Verallo-Rowell V.M., Verallo V., Graupe K., Lopez-Villafuerte L., and Garcia-Lopez M. Double-blind comparison of azelaic acid and hydroquinone in the treatment of melasma. Acta Derm Venereol Suppl (Stockh) 143 (1989) 58-61
30. Halder R., and Nordlund J.J. Topical treatment of pigmentary disorders. In: Nordlund J.J., Boissy R.E., Hearing V.J., King R.A., and Ortonne J.P. (Eds). The pigmentary system physiology and pathology (1998), Oxford University Press, New York 969-975
31. Kligman A.M., and Willis I. A new formula for depigmenting human skin. Arch Dermatol 111 (1975) 40-48
32. Griffiths C.E., Finkel L.J., Ditre C.M., Hamilton T.A., Ellis C.N., and Voorhees J.J. Topical tretinoin (retinoic acid) improves melasma: a vehicle-controlled, clinical trial. Br J Dermatol 129 (1993) 415-421
33. Kimbrough-Green C.K., Griffiths C.E., Finkel L.J., Hamilton T.A., Bulengo-Ransby S.M., Ellis C.N., et al. Topical retinoic acid (tretinoin) for melasma in black patients: a vehicle-controlled clinical trial. Arch Dermatol 130 (1994) 727-733
34. In: Murray L. (Ed). Physicians' desk reference. 57th ed. (2003), Thomson PDR, Montvale, NJ p. 545, 945, 1387
35. Thomas III J.R., and Doyle J.A. The therapeutic uses of topical vitamin A acid. J Am Acad Dermatol 4 (1981) 505-513
36. USP DI: drug information for the health care professional (2004), MICROMEDEX Thomson Health Care pp. 459-60
37. Kanwar A.J., Dhar S., and Kaur S. Treatment of melasma with potent topical corticosteroids. Dermatology 188 (1994) 170
38. Neering H. Treatment of melasma (chloasma) by local application of a steroid cream. Dermatologica 151 (1975) 349-353
39. Robertson D.B., and Maibach H.I. Topical corticosteroids. Int J Dermatol 21 (1982) 59-67
40. Taylor S.C., Torok H., Jones T., Lowe N., Rich P., Tschen E., et al. Efficacy and safety of a new triple-combination agent for the treatment of facial melasma. Cutis 72 (2003) 67-72
41. Lesnik R.H., Mezick J.A., Capetola R., and Kligman L.H. Topical all-trans-retinoic acid prevents corticosteroid-induced skin atrophy without abrogating the anti-inflammatory effect. J Am Acad Dermatol 21 (1989) 186-190
42. McMichael A.J., Griffiths C.E., Talwar H.S., Finkel L.J., Rafal E.S., Hamilton T.A., et al. Concurrent application of tretinoin (retinoic acid) partially protects against corticosteroid-induced epidermal atrophy. Br J Dermatol 135 (1996) 60-64
43. Torok H.M., Jones T., Rich P., Smith S., and Tschen E. Hydroquinone 4%, tretinoin 0.05%, fluocinolone acetonide 0.01%: a safe and efficacious 12-month treatment for melasma. Cutis 75 (2005) 57-62
44. Nazzaro-Porro M., and Passi S. Identification of tyrosinase inhibitors in cultures of Pityrosporum. J Invest Dermatol 71 (1978) 205-208
45. Akamatsu H., Komura J., Asada Y., Miyachi Y., and Niwa Y. Inhibitory effect of azelaic acid on neutrophil functions: a possible cause for its efficacy in treating pathogenetically unrelated diseases. Arch Dermatol Res 283 (1991) 162-166
46. Lowe N.J., Rizk D., Grimes P., Billips M., and Pincus S. Azelaic acid 20% cream in the treatment of facial hyperpigmentation in darker-skinned patients. Clin Ther 20 (1998) 945-959
47. Balina L.M., and Graupe K. The treatment of melasmaz: 20% azelaic acid versus 4% hydroquinone cream. Int J Dermatol 30 (1991) 893-895
48. Kakita L.S., and Lowe N.J. Azelaic acid and glycolic acid combination therapy for facial hyperpigmentation in darker-skinned patients: a clinical comparison with hydroquinone. Clin Ther 20 (1998) 960-970
49. Lim J.T. Treatment of melasma using kojic acid in a gel containing hydroquinone and glycolic acid. Dermatol Surg 25 (1999) 282-284
50. Garcia A., and Fulton Jr. J.E. The combination of glycolic acid and hydroquinone or kojic acid for the treatment of melasma and related conditions. Dermatol Surg 22 (1996) 443-447
51. Bleehen S.S. The treatment of hypermelanosis with 4-isopropylcatechol. Br J Dermatol 94 (1976) 687-694
52. Jimbow K. N-acetyl-4-S-cysteaminylphenol as a new type of depigmenting agent for the melanoderma of patients with melasma. Arch Dermatol 127 (1991) 1528-1534
53. Wong M., and Jimbow K. Selective cytotoxicity of N-acetyl-4-S-cysteaminylphenol on follicular melanocytes of black mice. Br J Dermatol 124 (1991) 56-61
54. Leenutaphong V., Nettakul A., and Rattanasuwon P. Topical isotretinoin for melasma in Thai patients: a vehicle-controlled clinical trial. J Med Assoc Thai 82 (1999) 868-875
55. Dogra S., Kanwar A.J., and Parsad D. Adapalene in the treatment of melasma: a preliminary report. J Dermatol 29 (2002) 539-540
56. Nerya O., Vaya J., Musa R., Izrael S., Ben Arie R., and Tamir S. Glabrene and isoliquiritigenin as tyrosinase inhibitors from licorice roots. J Agric Food Chem 51 (2003) 1201-1207
57. Amer M., and Metwalli M. Topical liquiritin improves melasma. Int J Dermatol 39 (2000) 299-301
58. Kameyama K., Sakai C., Kondoh S., Yonemoto K., Nishiyama S., Tagawa M., et al. Inhibitory effect of magnesium L-ascorbyl-2-phosphate (VC-PMG) on melanogenesis in vitro and in vivo. J Am Acad Dermatol 34 (1996) 29-33
59. Ni Z., Mu Y., and Gulati O. Treatment of melasma with Pycnogenol. Phytother Res 16 (2002) 567-571
60. Yamakoshi J., Sano A., Tokutake S., Saito M., Kikuchi M., Kubota Y., et al. Oral intake of proanthocyanidin-rich extract from grape seeds improves chloasma. Phytother Res 18 (2004) 895-899
61. Grimes P.E. The safety and efficacy of salicylic acid chemical peels in darker racial-ethnic groups. Dermatol Surg 25 (1999) 18-22
62. Matarasso S.L., and Glogau R.G. Chemical face peels. Dermatol Clin 9 (1991) 131-150
63. Chun E.Y., Lee J.B., and Lee K.H. Focal trichloroacetic acid peel method for benign pigmented lesions in dark-skinned patients. Dermatol Surg 30 (2004) 512-516
64. Cuce L.C., Bertino M.C., Scattone L., and Birkenhauer M.C. Tretinoin peeling. Dermatol Surg 27 (2001) 12-14
65. Karam P.G. 50% Resorcinol peel. Int J Dermatol 32 (1993) 569-574
66. Javaheri S.M., Handa S., Kaur I., and Kumar B. Safety and efficacy of glycolic acid facial peel in Indian women with melasma. Int J Dermatol 40 (2001) 354-357
67. Lim J.T., and Tham S.N. Glycolic acid peels in the treatment of melasma among Asian women. Dermatol Surg 23 (1997) 177-179
68. Sarkar R., Kaur C., Bhalla M., and Kanwar A.J. The combination of glycolic acid peels with a topical regimen in the treatment of melasma in dark-skinned patients: a comparative study. Dermatol Surg 28 (2002) 828-832
69. Kunachak S., Leelaudomlipi P., and Wongwaisayawan S. Dermabrasion: a curative treatment for melasma. Aesthetic Plast Surg 25 (2001) 114-117
70. Moreno Arias G.A., and Ferrando J. Intense pulsed light for melanocytic lesions. Dermatol Surg 27 (2001) 397-400
71. Wang C.C., Hui C.Y., Sue Y.M., Wong W.R., and Hong H.S. Intense pulsed light for the treatment of refractory melasma in Asian persons. Dermatol Surg 30 (2004) 1196-1200
72. Goldberg D.J. Laser treatment of pigmented lesions. Dermatol Clin 15 (1997) 397-407
73. Anderson R.R., Margolis R.J., Watenabe S., Flotte T., Hruza G.J., and Dover J.S. Selective photothermolysis of cutaneous pigmentation by Q-switched Nd:YAG laser pulses at 1064, 532, and 355 nm. J Invest Dermatol 93 (1989) 28-32
74. Nelson J.S., and Applebaum J. Treatment of superficial cutaneous pigmented lesions by melanin-specific selective photothermolysis using the Q-switched ruby laser. Ann Plast Surg 29 (1992) 231-237
75. Chan H.H., Fung W.K., Ying S.Y., and Kono T. An in vivo trial comparing the use of different types of 532 nm Nd:YAG lasers in the treatment of facial lentigines in Oriental patients. Dermatol Surg 26 (2000) 743-749
76. Tse Y., Levine V.J., McClain S.A., and Ashinoff R. The removal of cutaneous pigmented lesions with the Q-switched ruby laser and the Q-switched neodymium: yttrium-aluminum-garnet laser: a comparative study. J Dermatol Surg Oncol 20 (1994) 795-800
77. Goldberg D.J. Benign pigmented lesions of the skin: treatment with the Q-switched ruby laser. J Dermatol Surg Oncol 19 (1993) 376-379
78. Taylor C.R., and Anderson R.R. Ineffective treatment of refractory melasma and postinflammatory hyperpigmentation by Q-switched ruby laser. J Dermatol Surg Oncol 20 (1994) 592-597
79. 2 laser followed by Q-switched alexandrite laser: a pilot study. Dermatol Surg 25 (1999) 494-497
80. 2 laser and Q-switched alexandrite laser compared with Q-switched alexandrite laser alone for refractory melasma: split-face design. Dermatol Surg 29 (2003) 59-64
81. Manaloto R.M., and Alster T. Erbium:YAG laser resurfacing for refractory melasma. Dermatol Surg 25 (1999) 121-123
82. Halder R., and Nordlund J.J. Laser treatment of pigmentary disorders. In: Nordlund J.J., Boissy R.E., Hearing V.J., King R.A., and Ortonne J.P. (Eds). The pigmentary system physiology and pathphysiology (1998), Oxford University Press, New York 995-997
83. Grekin R.C., Shelton R.M., Geisse J.K., and Frieden I. 510-nm Pigmented lesion dye laser: its characteristics and clinical uses. J Dermatol Surg Oncol 19 (1993) 380-387
84. Health Canada. Drug product database. Available from: URL: http://www.hc-sc.gc.ca/hpb/drugs-dpd. Accessed April 9, 2005.